WASHINGTON—Donald Patrick McDonnell, Ph.D., has been awarded the Endocrine Society’s John D. Baxter Prize for Entrepreneurship for discovering hormone therapies for treating breast and prostate cancer ...
CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its ...
(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low ...
(RTTNews) - Crinetics Pharmaceuticals Inc. (CRNX) is approaching a watershed moment in its corporate and clinical trajectory. On September 25, 2025, the FDA is expected to announce its decision on the ...
July 16 (Reuters) - GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San ...
Tribune Online on MSN
Nigeria faces drug access crisis for diabetes, endocrine conditions – ACEN president
The President of the Association of Clinical Endocrinologists of Nigeria (ACEN), Professor Williams Balogun, said Nigeria is experiencing a full-blown crisis in access to medicines for diabetes and ...
AstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy – even if they had very low levels of the ...
June 2 (Reuters) - AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab Enhertu slows the progression of breast cancer by about five months in women whose disease worsened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results